1 / 13

Ophthalmic surgical clinic “ Rascheskoff ”, Kazan, Russia Drs. O.Ziyatdinova , L.Safiullina

European Association for Vision and Eye Research – Crete, Oct 5-8, 2011 . Ranibizumab for the Treatment of Exudative Age-Related Macular Degeneration Associated With Retinal Pigment Epithelial Detachment.

maddy
Télécharger la présentation

Ophthalmic surgical clinic “ Rascheskoff ”, Kazan, Russia Drs. O.Ziyatdinova , L.Safiullina

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. European Association for Vision and Eye Research – Crete, Oct 5-8, 2011 Ranibizumab for the Treatment of Exudative Age-Related Macular DegenerationAssociated With Retinal Pigment Epithelial Detachment Ophthalmic surgical clinic “Rascheskoff”, Kazan, RussiaDrs. O.Ziyatdinova, L.Safiullina

  2. Dr OlesyaZiyatdinova(the presenter) has no financial interest in the subject matter of this topic Financial Disclosure

  3. Purpose Toevaluatetheefficacyofintravitrealranibizumabineyeswithexudativeage-relatedmaculardegenerationassociatedwithretinalpigmentepithelialdetachment. • Materials and methods The study included 15 patients (15 eyes) withexudativeage-relatedmaculardegenerationassociatedwithretinalpigmentepithelialdetachment.

  4. 5 eyes with foveal involvement 10 eyes without foveal involvement

  5. Duration of disease: from 3 to 12 months Observation time: 12 months Number of injections: from 1 to 6 times

  6. Technique • Injection of 0,5 mg (0,05ml) of ranibizumab into vitreous body • Lower quadrant at a distance of 4 mm from limbus, needle 30G • Slow introduction • IOP control and instillation of antibiotics after operation

  7. Technique

  8. Criteria of efficacy Visual acuity (BCVA, UCVA) Ophthalmoscopy OCT

  9. Results Average BCVA increased from 20/100 to 20/50 and the average retinal thickness decreased from 367 +/-111 mkm to 281+/- 104 mkmin 8 eyes (53,4%) without foveal involvement.

  10. Results BCVA remainedstablein 5 eyes (33,3%) but there was a decrease onlyin 2eyes (13,3%) with foveal involvement. 3 eyes (20%) showeddisease stabilization after 1st injection 12 eyes (80%) required re-injection of the ranibizumab for 1-2 months

  11. OCT dynamics Before 1 month later 3 months later

  12. Conclusions • Intravitrealranibizumabwaseffectiveinimprovingorstabilizingvisionofpatientswithexudativeage-relatedmaculardegenerationassociatedwithretinalpigmentepithelialdetachment. • Thefunctionalresultswerebetterineyeswithoutfovealinvolvementwithretinalpigmentepithelialdetachment. • Visual acuity and OCT data are reliable criteria for evaluatingtheefficacyofintravitrealranibizumabineyeswithexudativeage-relatedmaculardegenerationassociatedwithretinalpigmentepithelialdetachment.

  13. Seeing is believing… Thank you!

More Related